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erythromycin therapy for sinobronchial syndrome 
Y. ISHIURA*, M. FUJIMURA, M. SAITO, K. SHIBATA, M. NOMURA, Y. NAKATSUMI AND 
T. MATSUDA 
Third Department of Internal Medicine, Kanazawa University School of Medicine, Kanazawa, Japan 
It has been established that long-term low-dose erythromycin therapy (EM therapy) is very effective for 
sinobronchial syndrome, a common condition in Japan characterized by chronic upper and lower airway 
inflammation. The effect does not result from its bacteriocidal activity and the detailed mechanisms are not 
known. It takes 3-6 months for EM therapy to improve the symptoms. This study was designed to evaluate 
the additive effect of continuous low dosage or intermittent usual dosage of ofloxacin (OFLX) on EM therapy 
in patients with sinobronchial syndrome. 
Patients with sinobronchial syndrome were randomly allocated to receive one of the following four 
regimens. Patients in Group A received both low-dose OFLX and EM therapy daily for 6 months. Patients in 
Group B received EM therapy and intermittent treatment of OFLX for 6 months. Patients in Group C 
underwent EM therapy for 6 months. Patients in Group D received neither OFLX nor EM therapy. 
All patients were given carbocystein for more than 2 months before starting each treatment and during the 
study period. 
In patients receiving OFLX and/or EM therapy, these antimicrobial agents were well-tolerated during the 
treatment period. Amount of sputum in the morning was significantly less in Group C than in Group D after 
3-6 months, and decreased significantly in Group A as compared with Group B after 2 weeks, Group C after 
2 weeks to 2 months, and Group D after 2 weeks to 6 months. Other symptoms such as number of 
expectorations, difficulty of expectoration and severity of cough also improved rapidly in Group A. 
These findings suggest that it is useful to add low-dose OFLX to EM therapy for sinobronchial syndrome, 
especially within l-2 months from starting treatment, and it may be cost-effective as this combination therapy 
can shorten the treatment period of EM therapy. 
Introduction 
Sinobronchial syndrome (SBS) (1,2) is a common 
airway disease in Japan, which consists of chronic 
sinusitis and chronic non-specific inflammation of 
lower airways such as diffuse bronchoectasis (3), 
diffuse panbronchiolitis (4) and chronic bronchitis, 
which is not related to smoking. Sinobronchial 
syndrome was found in 55.4% of 74 patients with 
chronic lower respiratory infectious disease by 
Suzaki et al. (5). They suggested that a gene con- 
trols susceptibility to SBS, especially diffuse pan- 
bronchiolitis which was significantly associated with 
HLA-Bw 54; this was found specifically in Japanese 
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and not in Caucasians. Sinobronchial syndrome has 
had a poor prognosis until long-term low-dose 
erythromycin therapy (EM therapy) was discovered 
to be extremely effective (69). Although EM 
therapy has been established to have an excellent 
effect in SBS (lo), 3-6 months are required to 
improve the symptoms and signs. Patients with 
acute exacerbation of SBS are usually treated with 
antimicrobial agents such as cephalosporins or new 
quinolones. 
Ofloxacin (OFLX) is one of the new quinolones, 
commonly prescribed and characterized by excellent 
antimicrobial effects and few adverse reactions (11). 
This study was designed to assess the effective- 
ness, acceptability and toxicity of a continuous 
long-term regimen of low-dose OFLX 
(200 mg day - ‘) or an intermittent usual-dose 
OFLX (600 mg day-‘) added to EM therapy in 
patients with SBS. 
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Tuble I Patient characteristics and pulmonary function before and after treatment 
Group A* Group B* Group C* Group D* 
Number of patients 
Male:Female 
Age (years) 
Height (cm) 
Weight (kg) 
Smoking Yes:No 
Duration of illness (yr) 
Pulmonary function tests 
FVC (1) 
FVC (%pred) 
FEV, (1) 
FEV, (%pred) 
FEV,/FVC ratio (%) 
Arterial blood gas analysis 
PaO, 
PaCO, 
before 2.55 i 0.34 
after 2.73 i 0.43 
before 88.4 f 8.1 
after 92.2 f 10.1 
before 1.86 f 0.29 
after 1.98 f 0.37 
before 85.2 zk X.4 
after 72.0f 11.2 
before 73.2 zk 3.7 
after 71.5 3~ 5.2 
before 
after 
before 
after 
66.0 f 3.0 
72.5 f 2.0 
44.6 f 0.5 
41.5 f 1.4 
13 
5:8 
59.0 f 3.7 
156.9 f 2.7 
51.7 f 3.1 
3:lO 
5.8 i 1.9 
10 
1o:o 
59.8 LIZ 4.5 
163.4 3 2.3 
54.2 i 3.7 
5:5 
9.8 f 1.8 
2.65 f 0.33 
2.93 zk 0.35 
76.3 f 8.7 
84.6 f 8.9 
1.94 f 0.29 
1.98 + 0.32 
73.1 + 11.2 
76.0 f IO.8 
65.5 f 3.7 
64.3 f 4.0 
63.5 zk 1.6 
72.2 * 3.4 
46.5 f 2.4 
45.4 LIZ 2.5 
11 
5:6 
52.1 f 5.1 
158.0 f 2.7 
55.0 * 3.5 
1:lO 
8.8 f 3.4 
2.5 1 f 0.23 
3.05 f 0.30 
86.2 f 5.4 
97.7 f 3.6 
1.87 + 0.21 
2,34&0.19 
84.2 f 7.8 
68.5 + 11.6 
79.2 + 3.7 
80.1 + 4.6 
65.4 f 3.4 
75.0 f 2.5 
45.5 f 1.7 
41.9 f 2.5 
10 
5:5 
55.8 f 4.2 
154.3 f 1.7 
52.5 f 2.8 
2:8 
4.5 f 1.5 
2.59f0.13 
244 * 0.14 
93.5 f 6.7 
90.4 f 7.8 
1.58 * 0.08 
1.70 * 0.05 
74.1 + 5.2 
65.7 i 4.8 
65.9 i 2.3 
71.4 f 2.7 
73.1 f 4.9 
74.4 f 2.9 
41.5 * 1.3 
44.2 f 1.2 
*Group A: EM (600 mg day - ‘), carbocystein (1500 mg day-‘) and OFLX (200 mg day- ‘) every day; Group B: 
EM (600 mg day - ‘) and carbocystein (1500 mg day ‘) every day and OFLX (600 mg day ‘) for 1 week every 3 weeks; 
Group C: EM (600 mg day - ‘) and carbocystein (1500 mg day - ‘) every day; Group D: carbocystein (1500 mg day - ‘), 
EM, erythromycin; OFLX, ofloxacin. All values given as mean f SEM. 
Materials and Methods 
SUBJECTS 
A total of 5 1 patients (16 Group A; 10 Group B; 13 
Group C; 11 Group D) were followed in this prospec- 
tive randomized open trial. The number of patients in 
each group was not equal as some patients declined 
to be entered in this study. Seven patients were 
excluded for various reasons before the start of 
chemotherapy. Three patients were withdrawn 
because of complicating bronchorrhoea, another 
patient had diabetes, and three patients were early 
defaulters. Therefore, 44 patients (13 Group A; 10 
Group B; 11 Group C; 10 Group D) were given 
treatment regimens. Of the 44 patients (Table l), 56% 
were male (25 males; 19 females), and aged 24-83 
years. Although there was a mismatch of sex in 
Group B, significant differences in other factors 
including respiratory function test were not detected. 
Mild suppression in arterial oxygen pressure and 
obstruction of small airways were observed in these 
patients as previously reported on SBS (12). 
Sinobronchial syndrome (1) was diagnosed based 
on the following criteria (12,13): (i) productive cough 
on most days for at least 3 months for 2 consecutive 
years; (ii) chronic sinusitis diagnosed based on symp- 
toms (postnasal drip, nasal discharge and nasal 
obstruction), physical examinations and plain roent- 
genogram as indicated by opacities or air-fluid levels 
of one or more paranasal sinuses; (iii) no history 
suggesting to the attending physician that they had 
bronchial asthma; (iv) no history of wheezing syn- 
drome (14); (v) no significant emphysema docu- 
mented by chest computed tomographic scan. 
Patients included in this study had fulfilled the fol- 
lowing criteria: (i) the patients were willing to accept 
the 6-months chemotherapy for SBS; (ii) they were 
older than 16 years of age; (iii) they did not have 
other respiratory infections; (iv) they had not taken 
other antimicrobial agents in the previous 2 weeks; 
(v) they did not have a history of allergic reactions 
for new quinolones; (vi) they were not suffering from 
other disorders such as diabetes, liver dysfunction, 
renal insufficiency, etc., (vii) they were not pregnant 
women. 
The study protocol was approved by the Ethics 
Committee in our hospital and each subject gave 
informed consent. 
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Fig, I Time course of amount of sputum in the morning (ml h ‘, mean f SEM) in each treatment group. Amount of 
sputum in the morning was shown as the average in 1 week. Group A (n= 13, solid bar), continuous low-dose ofloxacin 
(OFLX) (200 mg day ‘) added to the continuous low-dose erythromycin (EM) (200 mg three times a day) therapy; Group 
B (n= 10, striped bar), intermittent usual dose OFLX (200 mg three times a day for 1 week every 3 weeks) added to the EM 
therapy; Group C (n= 11, stippled bar), EM therapy; Group D (n= 10, open bar), placebo. Carbocystein (500 mg three times 
a day) was given in all patients for 8 weeks or more prior to and during the test period. W, week; M, month. 
TREATMENT REGIMENS 
Prior to the start of the study, all patients were 
randomly allocated to four treatment regimens: (13, 
10, 11 and 10 patients in Groups A, B, C and D, 
respectively). The A regimen consisted of EM 
therapy (200 mg three times a day) and daily low- 
dose OFLX (200 mg day ~ ‘) for 6 months. The B 
regimen consisted of EM therapy and intermittent 
administration of usual-dose OFLX (200 mg three 
times a day as commonly given in Japan for 1 week 
every 3 weeks) for 6 months. The C regimen consisted 
of EM therapy for 6 months. Patients in the D 
regimen did not receive any antimicrobial agents. All 
patients were given carbocystein (500 mg three times 
a day) for 2 weeks before starting each tested treat- 
ment and during the test period to confirm the 
diagnosis and to act as placebo. 
No patients were allowed to take other anti- 
microbial agents, corticosteroids or antiphlogistic 
agents during the test period. 
PRE-TREATMENT INVESTIGATIONS 
Prior to the commencement of treatment, all 
patients were subjected to the following tests: (i) 
amount of morning sputum (ml h - ‘); (ii) number of 
expectorations: (iii) difficulty in expectoration; (iv) 
severity of cough; (v) posterio-anterior chest radio- 
graph; (vi) haemoglobin, total and differential white 
blood cell count; (vii) serum transaminases, lactic 
dehydrogenase, alkaline phosphatase, y- glutamyl- 
transpeptidase, leucine aminopeptidase and total 
bilirubin; (vii) blood urea, serum creatinine and 
serum uric acid; (ix) urinalysis; (x) C-reactive protein 
and erythrocyte sedimentation rate; (xi) arterial 
blood gas analysis; (xii) respiratory function test; 
(xiii) sputum culture for pathologic organisms and 
their drug sensitivity. 
INVESTIGATIONS DURING TREATMENT AND FOLLOW-UP 
The clinical symptoms mentioned above were 
recorded on a diary card every day during the test 
period. The effectiveness of treatment on number of 
expectorations and severity of cough was classified 
into: (i) ineffective, scored 0; (ii) slightly effective, 
scored 1; (iii) effective, scored 2; and (iv) excellent, 
scored 3. The effectiveness of treatment on difficulty 
of expectoration was classified into: (i) easy, scored 0; 
(ii) difficult, scored 1 and (iii) more difficult, scored 2; 
over 6 months of treatment. Blood, urine and sputum 
were examined at 2 weeks and then once every 
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Fig 2 Time course of number of expectorations in each treatment group. Group A (n= 13, solid bar), continuous low-dose 
ofloxacin (OFLX) (200 mg day- ‘) added to the continuous low-dose erythromycin (EM) (200 mg three times a day) 
therapy; Group B (n= 10, striped bar), intermittent usual dose OFLX (200 mg three times a day for 1 week every 3 weeks) 
added to the EM therapy; Group C (n= 11, stippled bar), EM therapy; Group D (n= 10, open bar), placebo. Carbocystein 
(500 mg three times a day) was given in all patients for 8 weeks or more prior to and during the test period. W, week; 
M, month. 
month. Further specimens were collected if indicated 
clinically. Pulmonary function tests were performed 
at 1. 3 and 6 months. 
DATA ANALYSIS 
Values are presented as mean f SEM. Differences 
among four groups were analysed by non-parametric 
ANOVA, and those between any pair of groups were 
determined using Mann-Whitney U-test. These 
analyses were performed using the software StatView 
II (Abacus Concepts, Berkeley, CA, U.S.A.). A P 
value of less than 0.05 was considered statistically 
significant. 
Results 
CLINICAL SYMPTOMS 
Time courses of sputum amount during 1 h in the 
morning in the four groups are shown in Fig. 1. The 
sputum amount was significantly less at 2 weeks to 
6 months in Group A, at 2-6 months in Group B and 
at 3-6 months in Group C as compared with Group 
D. The sputum amount decreased significantly more 
rapidly in Group A as compared with Group B at 
2 weeks, Group C at 2 weeks and 1 and 2 months, 
and Group D at 2 weeks and l-6 months. Number of 
expectorations is shown in Fig. 2. Significant decrease 
was seen at l-6 months in Group A when compared 
with Group D. Time course of difficulty of expecto- 
ration are shown in Fig. 3. There was significant 
improvement at 2 weeks to 6 months in Group A, 
and at 2-6 months in Group C as compared with 
Group D. Time courses of severity of cough are 
shown in Fig. 4. There was a significant improvement 
at l-6 months in Group A and at 6 months in Group 
C compared with Group D. In Group A, severity of 
cough was significantly more mild at 3, 5 and 6 
months than that in Group B, and at 3 months than 
that in Group C, respectively. 
RESULTS OF LABORATORY FINDINGS 
Results of respiratory function test and arterial 
oxygen pressure are shown in Table 1. Although it is 
not statistically significant in this study, improve- 
ments as previously reported on EM therapy (12) 
were observed in the present study. 
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Fig. 3 Time course of difficulty of expectoration in each treatment group. Group A (n= 13, solid bar), continuous low-dose 
ofloxacin (OFLX) (200 mg day - ‘) added to the continuous low-dose erythromycin (EM) (200 mg three times a day) 
therapy; Group B (n= 10, striped bar), intermittent usual dose OFLX (200 mg three times a day for 1 week every 3 weeks) 
added to the EM therapy; Group C (n= 11, stippled bar), EM therapy; Group D (n= 10, open bar), placebo. Carbocystein 
(500 mg three times a day) was given in all patients for 8 weeks or more prior to and during the test period. W, week; 
M, month. 
ADVERSE REACTIONS 
Possible adverse reactions were reported in two 
(4.5%) of the 44 patients during the study. Mild liver 
dysfunction and peripheral blood eosinophilia were 
found in one patient of Group B and mild liver 
dysfunction was seen in one patient of Group C. 
Their treatment was discontinued at 2 months and 
these adverse effects rapidly disappeared. Other 
adverse drug reactions including gastrointestinal 
symptoms (nausea and vomiting) and eruptions were 
not detected in the present study. 
RESULTS OF SPUTUM SMEAR AND BACTERIOLOGICAL 
RELAPSE 
Results of sputum smear are shown in Table 2. 
Although acute exacerbation during the test period 
was not reported, the bacteriological relapse after 
treatment was reported in one patient of Group C; 
from normal flora to Pseudomonas maltophilia. Bac- 
teriological findings indicate that other patients 
responded to each treatment regimen because inci- 
dence of normal flora in their sputum smear 
increased and pyogenic sputum culture did not 
increase. 
Discussion 
Sinobronchial syndrome (1,2) is a common chronic 
airway disease in Japan, which consists of chronic 
sinusitis and chronic non-specific inflammation of 
lower airways, such as diffuse bronchioectasis (3) 
diffuse panbronchiolitis (4) and chronic bronchitis. In 
the criteria of the American Thoracic Society (15), 
chronic bronchitis is the smoking-related bronchial 
disease. Many patients in Japan presenting with 
chronic productive cough who visit the chest clinic 
for diagnosis and treatment, are non-smokers and are 
diagnosed to have SBS, while chronic bronchitis is 
diagnosed in the small number of patients who 
smoke cigarettes (16). The severe obstructive form of 
SBS is known as diffuse panbronchiolitis (4). Gener- 
ally, chronic sinusitis precedes symptoms of lower 
respiratory tract inflammation. It is a special feature 
that the symptoms are successfully treated with 
long-term low-dose EM therapy (69). 
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Fig. 4 Time course of severity of cough in each treatment group. Group A (n=13, solid bar), continuous low-dose 
ofloxacin (OFLX) (200 mg day ‘) added to the continuous low-dose erythromycin (EM) (200 mg three times a day) 
therapy; Group B (n= 10, striped bar), intermittent usual dose OFLX (200 mg three times a day for 1 week every 3 weeks) 
added to the EM therapy; Group C (n= 11, stippled bar), EM therapy; Group D (n= 10, open bar), placebo. Carbocystein 
(500 mg three times a day) was given in all patients for 8 weeks or more prior to and during the test period. W, week; 
M, month. 
Erythromycin has proven to be an excellent 
orally active agent in patients with SBS (8) and of 
course with diffuse panbronchiolitis (6) a subtype 
of SBS (4). It has been reported that the maximal 
serum and sputum levels of EM are below the 
minimal inhibitory concentrations (MICs) of clini- 
cally pathogenic bacterial agents, so EM is con- 
sidered to respond for the patients with chronic 
lower respiratory infections by mechanisms other 
than its antimicrobial activity (6). This hypothesis is 
also supported by the presence of continuous infec- 
tion and acute exacerbation in EM-effective patients 
(6). Although the exact mechanisms of EM therapy 
are still unclear, some suggesting studies have been 
reported. Kadota et al. (7) suggested that EM 
impairs the capacity for pulmonary inflam- 
mation by reducing the intrapulmonary chemotactic 
gradient or the ability of the neutrophils to respond 
to chemotactic factors, ultimately reducing the 
migration of neutrophils to inflammatory sites. 
Recent investigators have reported that EM influ- 
ences the functions of immunocompetent cells (lo), 
the inhibition of superoxide generation by neu- 
trophils (17-19), and the reduction of the respira- 
tory glycoconjugate secretion (20). 
Patients in acute exacerbation are briefly adminis- 
tered other antimicrobial agents, such as cephalo- 
sporins and new quinolones, in addition to EM 
because Haemophilus influenzae and Streptoccus 
pneumoniae frequently induce the exacerbation 
(21,22), and patients with chronic lower respiratory 
tract infections often show rapid advances with long- 
lasting acute exacerbation, ending in a fatal outcome. 
Tanimoto et al. (23) have reported that treatment 
with EM or new quinolones showed a definite 
improvement of survival rate in diffuse pan- 
bronchiolitis. This prospective study was conducted 
with OFLX added to EM therapy for SBS, and 
the clinical efficacy of continuous low dosage and 
intermittent usual dosage of OFLX was evaluated. 
Ofloxacin was selected from the new quinolones 
due to its excellent antimicrobial effect against 
Haemophilus injluenzae and Streptococcus pneu- 
moniae and few adverse reactions in its long-term 
administration (24). This antimicrobial agent has 
proven to be excellent due to its good penetration of 
respiratory tissues (11) low cytotoxicity and strong 
inhibitory action against DNA gyrase (18) (the 
enzyme plays an important role in DNA replication, 
DNA repair and recombination). 
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Table 2 Bacterial findings in sputum before and after treatment 
Group A Group B Group C Group D* 
before after before after before after before after 
Bacterial culture 
Pseudomonas aeruginosa 2 1 2 2 2 1 2 1 
Klebsiella pneumoniae 1 0 0 1 1 1 3 2 
Haemophilis influenzae 2 2 4 1 4 0 2 2 
Staphylococcus aureus 0 0 1 1 0 0 0 0 
Streptococcus pneumoniae 2 1 2 0 1 0 0 0 
Others 0 0 0 0 0 1 0 0 
Normal flora 6 9 1 5 3 8 3 5 
*Group A: EM (600 mg day ‘), carbocystein (1500 mg day ‘) and OFLX (200 mg day ‘) 
every day; Group B: EM (600 mg day- ‘) and carbocystein (1500 mg day ‘) every day and 
OFLX (600 mg day- ‘) for 1 week every 3 weeks; Group C: EM (600 mg day- ‘) and 
carbocystein (1500 mg day ‘) every day; Group D: carbocystein (1500 mg day ‘). EM, 
erythrdmycin; OFLX, ofldxacin. 
The present study has shown the clinical efficacy of 
long-term administration of low-dose OFLX added 
to EM therapy in patients with SBS but some 
problems remained. The first problem is that less 
improvement in severity of cough and number of 
expectorations in patients of Group B (intermittent 
usual dose of OFLX) was indicated compared with 
the patients of group C (EM therapy) in its late 
treatment period (46 months). Although the exact 
cause is unknown, the authors speculate regarding 
the possibility of rebound phenomenon induced by 
repeatment of intermittent chemotherapy. The sec- 
ond problem is that low-dose OFLX added to EM 
therapy was significantly more effective in its initial 2 
months, but not at 3-6 months, as compared with 
EM therapy alone. The antimicrobial effect of OFLX 
is thought to be one of the mechanisms for the rapid 
improvement with added OFLX. Since EM and 
OFLX have clinical efficacy due to different mecha- 
nisms as mentioned above, additive antimicrobial 
effect of OFLX on the anti-inflammatory effects of 
EM may be responsible for the excellent effect. Thus 
it is thought to be useful to add continuous low-dose 
OFLX to EM therapy for SBS, especially in its early 
treatment period (l-2 months), but combination 
therapy should be discontinued after 3 months 
because clinical improvement did not differ between 
combination therapy and EM therapy alone from 
336 months in this study. These findings also suggest 
the cost-effectiveness for the treatment of SBS, 
because combination therapy may shorten the 
treatment period of EM therapy. 
Adverse reactions caused by OFLX have been 
reported in 5.5% of patients: gastrointestinal com- 
plaints (such as nausea, vomiting or heart burn; 
4.5%), hypersensitivity reactions (0.5%) and central 
nervous system disorders (2.3%) (11). It has been 
reported that adverse reactions of EM therapy are 
eruption, hepatic dysfunction and gastrointestinal 
symptoms (6). Since EM has potent stimulating 
effects of gastrointestinal motor activity (25) and is a 
motilin receptor agonist (26) gastrointestinal symp- 
toms after its oral administration are well-known 
adverse reactions. Nagai et al. (6) reported that 
gastrointestinal symptoms were not revealed in low- 
dose administration of EM. Fortunately, no adverse 
reactions related to gastrointestinal complaints, such 
as nausea, vomiting, heart burn, abdominal pain or 
diarrhoea, were found in this study by adding OFLX 
to low-dose EM therapy. 
From the limited review of literature and the 
results of this study, it appears that it is useful to add 
long-term low-dose OFLX to EM therapy for SBS, 
especially in the early treatment period, due to its 
rapid efficacy, few adverse reactions and excellent 
acceptability. Moreover it may be cost-effective it this 
combination therapy can reduce the treatment period 
of EM therapy by its beneficial points as mentioned 
above. Furthermore, large population studies will be 
needed to confirm the efficacy of adding OFLX or 
other new quinolones to the long-term low-dose EM 
therapy for SBS especially in its early treatment 
period. 
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